Does Blue Cross Blue Shield of Michigan Cover Ozempic?

BCBSM Formulary Placement for Ozempic

Blue Cross Blue Shield of Michigan lists Ozempic (semaglutide injection) on its commercial formulary as a preferred brand or specialty-tier medication for adults with type 2 diabetes. The drug has held this position since Novo Nordisk received FDA approval for the 0.5 mg and 1 mg pens in 2017, with the 2 mg dose added in 2022 1.

How Tier Placement Affects Your Cost

Formulary tier determines your out-of-pocket share. On most BCBSM PPO and HMO plans, Ozempic sits at Tier 3 or Tier 4. Tier 3 copays typically run $50 to $100 per fill, while Tier 4 (specialty) copays can reach $150 or require coinsurance of 20% to 33%. Members enrolled in BCBSM's Blue Care Network HMO products may see slightly different tier assignments. Always verify your tier through the BCBSM member portal or by calling the number on the back of your card.

Medicare Advantage Considerations

BCBSM administers several Medicare Advantage plans in Michigan. Medicare Part D covers Ozempic for type 2 diabetes but explicitly excludes coverage for obesity or weight loss under the Social Security Act. The Inflation Reduction Act capped Part D out-of-pocket insulin costs at $35 per month, but that cap does not apply to GLP-1 receptor agonists like Ozempic 2. Medicare Advantage members should check their Evidence of Coverage document for exact copay or coinsurance amounts, which can exceed $200 per month in the coverage gap.

Prior Authorization Requirements

Every BCBSM plan requires prior authorization (PA) for Ozempic. Your prescriber's office submits this request, and BCBSM typically responds within 72 hours for non-urgent cases or 24 hours for urgent requests.

Clinical Criteria You Must Meet

BCBSM's PA criteria for Ozempic generally require:

1. A confirmed diagnosis of type 2 diabetes mellitus (ICD-10 E11.x)
2. Current or recent HbA1c of 7.0% or higher documented within the past 90 days
3. Trial and failure of, intolerance to, or contraindication to metformin
4. Some plans require failure of a second oral agent (sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor)
5. The prescriber must be an M.D., D.O., or supervised advanced practice provider

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, which can strengthen a PA request 3.

What Happens if PA Is Denied

If BCBSM denies your PA, you receive a written explanation. You have 180 days to file an internal appeal. The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide reduced major adverse cardiovascular events by 26% compared to placebo in patients with type 2 diabetes and high cardiovascular risk 4. Citing this trial and the ADA Standards of Care in your appeal letter can strengthen the case. If the internal appeal fails, Michigan law allows an external review through an independent review organization at no cost to the member.

Coverage for Weight Loss vs. Type 2 Diabetes

This distinction matters enormously. Ozempic carries an FDA-approved indication only for type 2 diabetes and cardiovascular risk reduction, not for chronic weight management. Novo Nordisk markets semaglutide 2.4 mg under the brand name Wegovy for obesity 5.

The Off-Label Prescribing Gap

Physicians sometimes prescribe Ozempic off-label for weight loss in patients without diabetes. BCBSM will almost always deny these claims. The plan's clinical policy specifically requires a type 2 diabetes diagnosis. If your primary goal is weight management without a diabetes diagnosis, ask your prescriber about Wegovy, which BCBSM covers under a separate PA pathway on select plans that include an obesity benefit.

Plans With Obesity Riders

Some BCBSM employer-sponsored plans purchase an obesity pharmacotherapy rider that extends coverage to FDA-approved anti-obesity medications. These riders are not standard. Contact your employer's benefits department or BCBSM member services to confirm whether your specific plan includes this add-on. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo 6, data that has pushed more Michigan employers to add obesity coverage in recent plan years.

Expected Out-of-Pocket Costs

Your actual cost depends on plan design, pharmacy choice, and whether you have met your deductible.

Commercial Plan Cost Estimates

| Plan Type | Typical Tier | Estimated Copay per Fill | |---|---|---| | BCBSM PPO (employer-sponsored) | Tier 3 | $50 to $100 | | BCBSM PPO (individual marketplace) | Tier 3 or 4 | $75 to $150 | | Blue Care Network HMO | Tier 3 | $40 to $90 | | BCBSM Medicare Advantage | Tier 4 (specialty) | $100 to $250+ |

Without any insurance, Ozempic's wholesale acquisition cost is approximately $935 per month for the 1 mg pen. Novo Nordisk offers a savings card for commercially insured patients that can reduce the copay to as low as $25 per fill for up to 24 months, though Medicare and Medicaid beneficiaries are not eligible for this program 7.

Specialty Pharmacy Requirements

BCBSM may require you to fill Ozempic through a designated specialty pharmacy or its mail-order pharmacy, AllianceRx Walgreens Pharmacy. Using an out-of-network pharmacy could result in full retail pricing. Confirm your plan's preferred pharmacy network before filling.

Step Therapy and Therapeutic Alternatives

BCBSM applies step therapy to many GLP-1 receptor agonist claims. This means the plan wants documentation that less expensive therapies were tried first.

Common Step Therapy Sequence

A typical BCBSM step therapy pathway looks like this:

1. Metformin (first-line, per ADA guidelines)
2. Sulfonylurea or SGLT2 inhibitor (second-line oral agent)
3. GLP-1 receptor agonist (Ozempic, Trulicity, or Victoza)

Dulaglutide (Trulicity) may be preferred over Ozempic on some BCBSM formularies, which means the plan could require a trial of Trulicity before approving Ozempic. The SUSTAIN-7 trial directly compared semaglutide 1 mg to dulaglutide 1.5 mg and found semaglutide produced greater HbA1c reduction (1.8% vs 1.4%) and greater weight loss (6.5 kg vs 3.0 kg) at 40 weeks 8. Your prescriber can cite this head-to-head data to request an exception if Ozempic is not the preferred agent on your plan.

Other GLP-1 Options on BCBSM Formularies

If Ozempic is denied or cost-prohibitive, BCBSM formularies typically also cover:

• Trulicity (dulaglutide): Weekly injection, often preferred on BCBSM plans
• Rybelsus (oral semaglutide): Tablet form of semaglutide, 7 mg or 14 mg daily
• Mounjaro (tirzepatide): Dual GIP/GLP-1 agonist, may require separate PA

The SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.58% versus 1.86% with semaglutide 1 mg at 40 weeks, with greater weight loss as well 9. Discuss all formulary options with your prescriber.

How to Check Your Specific Coverage

Do not rely on general information alone. BCBSM administers hundreds of distinct plan designs across Michigan employers, individual marketplace plans, and Medicare Advantage products.

Three Ways to Verify

1. BCBSM Member Portal. Log into bcbsm.com, manage to "Find a Drug," and search for Ozempic. The tool shows your specific tier, PA requirements, and estimated cost.

2. Call Member Services. The phone number is on the back of your insurance card. Ask specifically: "Is Ozempic covered on my formulary, and what is my cost share at a preferred pharmacy?"

3. Ask Your Pharmacy. Any in-network pharmacy can run a test claim to show your real-time copay before you commit to filling.

Employer Plan Variability

Two BCBSM members working at different Michigan employers can have completely different Ozempic coverage. One employer's plan might place Ozempic at Tier 3 with a $50 copay and no step therapy. Another might require two oral agent failures, mandate Trulicity first, and impose a $150 specialty copay. The plan's Summary of Benefits and Coverage (SBC) document is the definitive source.

Filing an Appeal After a Denial

About 20% to 30% of initial GLP-1 receptor agonist prior authorizations are denied by commercial insurers, according to industry data. An appeal is worth pursuing.

Internal Appeal Process

Your prescriber should submit a letter of medical necessity that includes:

• Current HbA1c and trend over the past 6 to 12 months
• List of previously tried and failed medications with dates, doses, and reasons for discontinuation
• Relevant comorbidities (cardiovascular disease, chronic kidney disease, obesity)
• Specific clinical trial evidence supporting semaglutide over alternatives

The PIONEER-6 cardiovascular outcomes trial (N=3,183) confirmed that oral semaglutide did not increase cardiovascular risk, while the SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease 10. These data points carry weight in appeal reviews.

External Review Rights

Under Michigan's Patient's Right to Independent Review Act, if BCBSM upholds its denial on internal appeal, you can request an external review. An independent physician reviewer examines the case. The external review decision is binding on BCBSM. There is no cost to you for requesting this review.

Michigan Medicaid and Ozempic

Michigan Medicaid (administered through Managed Care Organizations like Molina, Meridian, and Priority Health) does cover Ozempic for type 2 diabetes with prior authorization. Medicaid PA criteria are often more restrictive than commercial plans. The Michigan Department of Health and Human Services maintains a preferred drug list that is updated quarterly 11.

Copays for Medicaid members are typically $1 to $3 per prescription under Michigan law, making Ozempic far more affordable for Medicaid-eligible patients than for those on high-deductible commercial plans.

Manufacturer and Patient Assistance Programs

If your BCBSM plan leaves you with a high copay, two programs may help.

Novo Nordisk Savings Card. Commercially insured patients can pay as little as $25 per monthly fill. Not available to government-insured (Medicare, Medicaid, Tricare) members.

Novo Nordisk Patient Assistance Program (PAP). Uninsured or underinsured patients earning below 400% of the federal poverty level may qualify for free Ozempic. Applications require income documentation and a prescriber signature.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends that clinicians help patients identify coverage pathways when cost is a barrier to GLP-1 therapy 12.